CRINETICS PHARMACEUTICALS
LIVE

Serial Number

97844252

Owner

Crinetics Pharmaceuticals, Inc.

Attorney

Danny M. Awdeh

First Use Date

Dec 7, 2018

Filing Date

Mar 17, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CRINETICS PHARMACEUTICALS Trademark

Serial Number: 97844252 • Registration: 7827659

CRINETICS PHARMACEUTICALS is a trademark filed by Crinetics Pharmaceuticals, Inc. on March 17, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Crinetics Pharmaceuticals, Inc. (16 trademarks)

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

March 17, 2023

Registration Date

June 10, 2025

First Use Anywhere

December 7, 2018

First Use in Commerce

December 7, 2018

Published for Opposition

January 30, 2024

Goods & Services

Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders

Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 10, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 10, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 17, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 17, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Mar 31, 2025 SUPC
USE AMENDMENT FILED
Sep 12, 2024 IUAF
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 12, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 12, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 12, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 12, 2024 EEXT
TEAS STATEMENT OF USE RECEIVED
Sep 12, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 26, 2024 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 28, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 28, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 28, 2024 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 22, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 19, 2023 XAEC
ASSIGNED TO LIE
Dec 19, 2023 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 18, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 18, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 18, 2023 CNEA
ASSIGNED TO EXAMINER
Dec 13, 2023 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Oct 9, 2023 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Oct 9, 2023 PARI
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 11, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 9, 2023 NWOS
NEW APPLICATION ENTERED
Mar 21, 2023 NWAP